How many drugs treat Heterotopic ossification?

Drug Landscape tracks 3 marketed treatments for Heterotopic ossification (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/heterotopic-ossification.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Heterotopic ossification — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heterotopic ossification (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Heterotopic ossification, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Didronel	ETIDRONIC ACID	Procter And Gamble	Bisphosphonate		1977-01-01
Etidronate	Etidronate	Organon and Co		Type IV secretion-like conjugative transfer relaxase protein TraI
Ethidronate	Ethidronate	Centre National d'Etudes Spatiales		Type IV secretion-like conjugative transfer relaxase protein TraI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Centre National d'Etudes Spatiales · 1 drug in Heterotopic ossification
Organon and Co · 1 drug in Heterotopic ossification
Procter And Gamble · 1 drug in Heterotopic ossification

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Heterotopic ossification:

Cite this brief

Drug Landscape (2026). Heterotopic ossification — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/heterotopic-ossification. Accessed 2026-06-10.

Heterotopic ossification full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing